title: Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial.
abstract: OBJECTIVE
  To assess the activity of baclofen, a potent gamma-aminobutyric acid-ergic agonist, against dysfunctional voiding (DV) and lower urinary tract symptoms (LUTS) in a clinical trial, as DV is a leading cause of LUTS in women, but there is no effective treatment.
  
  
  METHODS
  We conducted a randomized double-blind placebo-controlled crossover trial in 60 women with DV and LUTS between January 2003 and January 2006; patients were randomly assigned either baclofen 10 mg three times daily, then matching placebo for 4 weeks, or matching placebo then baclofen 10 mg three times daily for 4 weeks, separated by a 2-week washout period. Voiding diaries and multichannel urodynamics (at baseline, 4 and 10 weeks) were used to record the changes of voids/24 h and urodynamic variables. The primary efficacy endpoint was the change in voids/24 h, and the TL value (log[T/L]), a new electromyographic variables showing the extent of DV. Efficacy outcomes at 4 and 10 weeks were compared with the baseline data, using a crossover-designed analysis of variance model.
  
  
  RESULTS
  The efficacy analysis of the treatment showed that baclofen was associated with significantly fewer voids/24 h than placebo (mean difference from baseline 5.53 vs 2.70; P = 0.001) and a significant increase in TL (mean difference from baseline -1.78 vs 0.01, P = 0.001). No significant adverse events were reported.
  
  
  CONCLUSIONS
  A 4-week course of baclofen significantly reduced the number of voids/24 h and increased the TL value in women with DV confirmed by transdermal perineal electromyography. These encouraging results suggest that baclofen could be used for treating DV in women.
authors.affiliation: Department of Urology, Changzheng Hospital, Shanghai, China.
authors.forename: Danfeng
authors.initials: D
authors.lastname: Xu
authors.forename: Chuangyu
authors.initials: C
authors.lastname: Qu
authors.forename: Hong
authors.initials: H
authors.lastname: Meng
authors.forename: Jizhong
authors.initials: J
authors.lastname: Ren
authors.forename: Youhua
authors.initials: Y
authors.lastname: Zhu
authors.forename: Zhilian
authors.initials: Z
authors.lastname: Min
authors.forename: Yuele
authors.initials: Y
authors.lastname: Kong
mesh_terms: D000328:Adult; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004576:Electromyography / Q000379:methods; D005260:Female; D018755:GABA Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000502:physiology*
chemical_list: D018755:GABA Agonists; D001418:Baclofen